Normobaric Hyperoxia Slows Blood–Brain Barrier Damage and Expands the Therapeutic Time Window for Tissue-Type Plasminogen Activator Treatment in Cerebral Ischemia | Zendy

Jia Liang | Zendy; Zhifeng Qi | Zendy; Wenlan Liu | Zendy; Peng Wang | Zendy; Wenjuan Shi | Zendy; Wen Dong | Zendy; Xunming Ji | Zendy; Yumin Luo | Zendy; Ke Jian Liu | Zendy

Open Access

Normobaric Hyperoxia Slows Blood–Brain Barrier Damage and Expands the Therapeutic Time Window for Tissue-Type Plasminogen Activator Treatment in Cerebral Ischemia

Author(s) -

Jia Liang,

Zhifeng Qi,

Wenlan Liu,

Peng Wang,

Wenjuan Shi,

Wen Dong,

Xunming Ji,

Yumin Luo,

Ke Jian Liu

Publication year - 2015

Publication title -

stroke

Language(s) - English

Resource type - Journals

SCImago Journal Rank - 3.397

H-Index - 319

eISSN - 1524-4628

pISSN - 0039-2499

DOI - 10.1161/strokeaha.114.008599

Subject(s) - medicine , ischemia , blood–brain barrier , tissue plasminogen activator , pathogenesis , occludin , anesthesia , plasminogen activator , pharmacology , tight junction , central nervous system , biology , microbiology and biotechnology

Prolonged ischemia causes blood-brain barrier (BBB) damage and increases the incidence of neurovasculature complications secondary to reperfusion. Therefore, targeting ischemic BBB damage pathogenesis is critical to reducing neurovasculature complications and expanding the therapeutic time window of tissue-type plasminogen activator (tPA) thrombolysis. This study investigates whether increasing cerebral tissue PO2 through normobaric hyperoxia (NBO) treatment will slow the progression of BBB damage and, thus, improve the outcome of delayed tPA treatment after cerebral ischemia.

The content you want is available to Zendy users.

Already have an account? Click here to sign in.

Having issues? You can contact us here

Accelerating Research